The recent commentary by Lorraine Lipscombe gave the impression that the 10-study meta-analysis by Loke and colleagues yields a new finding that there might be an association between thiazolidinediones and an increased risk of fractures in women. In fact, this finding largely replicates an association reported 2 years ago in the publication of the results of ADOPT (A Diabetes Outcome and Progre...

BACKGROUND Insulin-sensitizing drugs of the thiazolidinedione class and metformin are commonly prescribed to treat diabetes in patients with heart failure despite strong warnings from the Food and Drug Administration against this practice. Whether this results in adverse outcomes is unknown. METHODS AND RESULTS We conducted a retrospective cohort study of 16,417 Medicare beneficiaries with di...

CONTEXT According to package inserts, metformin is contraindicated in diabetic patients receiving drug treatment for heart failure therapy, and thiazolidinediones are not recommended in diabetic patients with symptoms of advanced heart failure. Little is known about patterns of use of these antihyperglycemic drugs in diabetic patients with heart failure. OBJECTIVE To determine the proportions...

Poorly differentiated, metastatic thyroid cancer is difficult to treat. These tumors often do not concentrate radioactive iodine and may require chemotherapy, which is suboptimal and toxic. Nuclear hormone receptors peroxisome proliferator-activated receptor ; (PPAR;) and retinoid X receptor (RXR) are variably expressed in thyroid carcinoma cell lines. Expression of these receptors may predict ...

OBJECTIVE To evaluate the safety and effectiveness of triple therapy using insulin, metformin, and a thiazolidinedione following a course of dual therapy using insulin and metformin or insulin and a thiazolidinedione in type 2 diabetes. RESEARCH DESIGN AND METHODS Twenty-eight type 2 diabetic subjects using insulin monotherapy (baseline HbA(lc) level 8.5%) who had been randomly assigned to in...

1. Tang WHW, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003;41:1394–8. 2. Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 2003;27:147–61.